亚宝药业: 亚宝药业集团股份有限公司2025年半年度报告摘要

Core Points - The report indicates a significant decline in revenue for Yabao Pharmaceutical, with a 21.08% decrease in operating income compared to the previous year [1] - The total assets of the company decreased by 2.55% from the end of the previous year [1] - The net profit attributable to shareholders of the listed company showed a slight decrease of 0.18% [1] Financial Summary - Total assets at the end of the reporting period were CNY 3,453,585,568.80, down from CNY 3,543,942,574.34 [1] - Operating income for the reporting period was CNY 1,139,408,464.81, compared to CNY 1,443,686,437.98 in the same period last year [1] - Total profit was CNY 212,430,139.84, slightly down from CNY 212,806,112.58 [1] - Net profit attributable to shareholders, after deducting non-recurring gains and losses, was CNY 159,681,557.75, a decrease of 1.69% from CNY 162,424,025.15 [1] Shareholder Information - The largest shareholder, Shanxi Yabao Investment Group Co., Ltd., holds 13.47% of the shares [3] - The second-largest shareholder, Hong Kong Central Clearing Limited, holds 6.63% [3] - The total number of shareholders at the end of the reporting period was 49,007 [1]